Treatment of Plaque Psoriasis

Oct 16, 2019, 10:03am



On August 1 2019, the U.S. Food and Drug Administration (FDA) expanded the approved indication for Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older. The decision is supported, in part, by the Enstilar Pediatric Study (NCT02387853) in adolescents age 12 to 17 with psoriasis of the body and scalp.

Download Supplement